The estimated Net Worth of City Capital Llc Bay City C... is at least $18.3 million dollars as of 10 February 2014. City C owns over 466,667 units of Epizyme Inc stock worth over $4,692,331 and over the last 11 years City sold EPZM stock worth over $13,650,010.
City has made over 1 trades of the Epizyme Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently City sold 466,667 units of EPZM stock worth $13,650,010 on 10 February 2014.
The largest trade City's ever made was selling 466,667 units of Epizyme Inc stock on 10 February 2014 worth over $13,650,010. On average, City trades about 466,667 units every 0 days since 2014. As of 10 February 2014 City still owns at least 3,192,062 units of Epizyme Inc stock.
You can see the complete history of City C stock trades at the bottom of the page.
Over the last 11 years, insiders at Epizyme Inc have traded over $122,255,844 worth of Epizyme Inc stock and bought 45,285,781 units worth $322,885,823 . The most active insiders traders include Forest Baskett, Scott D Sandell et Peter J Barris. On average, Epizyme Inc executives and independent directors trade stock every 17 days with the average trade being worth of $394,367. The most recent stock trade was executed by Grant C. Bogle on 9 August 2022, trading 1,217,500 units of EPZM stock currently worth $1,704,500.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
Epizyme Inc executives and other stock owners filed with the SEC include: